Overview

Cancer is a leading cause of death worldwide. According to the World Health Organization (WHO), cancer accounted for 7.4 million deaths—about 13 percent of all deaths—worldwide. According to Decision Resources, the targeted cancer drug market will double in value, from $25 billion in 2008 to $51 billion in 2015.

VBL Therapeutics is committed to developing first-in-class treatments for cancer that will offer new hope to patients and their families. Leveraging our innovative, proprietary, award-winning VTS™ (Vascular Targeting System) platform technology, we have discovered and progressed VB-111, first-in-class dual therapy anti-angiogenic and vascular disruptive agent (VDA), into clinical trials and expect to launch Phase 2 clinical trials in 2010 in thyroid cancer.